| International FP- 003 |
| Timing of Complete Absence of Polypoidal Lesions Following Fixed Dosing Aflibercept Treatments in Polypoidal Choroidal Vasculopathy |
| Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand(1),
Retina Division, Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand(2),
Retina Division, Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand(3),
Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, USA(4) |
| Phit Upaphong(1), Voraporn Chaikitmongkol(2), Direk Patikulsila(2), Pichai Jirarattanasopa(3), Janejit Choovuthayakorn(2), Neil M. Bressler(4) |
|
Purpose : To explore the timing of complete absence of polypoidal lesions on ICGA following intravitreous aflibercept treatments in PCV
Methods : Eyes with newly-diagnosed PCV, by EVEREST criteria, between April 2016 and December 2017 were included. Eligible eyes received fix-dosing aflibercept injections (3 monthly injections then every 8 weeks) for 12 months. ICGA performed at baseline and every 8 weeks (week 8, 16, 24, 32, 40, 48, 52). Two ophthalmologist graders reviewed ICGA at each visit and determined polypoidal status i.e., complete regression (absence of polypoidal lesions), incomplete regression (partial absence of polypoidal lesions), or no regression (no change on ICGA). Final decision made by agreements of both graders with open adjudications.
Results : Among 40 study eyes (38 participants; 100% Thai, 61% female, mean [SD] age 64 [±8.3] years), included serous (15%), serosanguinous/ exudative (66%), and hemorrhagic (18%) maculopathies. Baseline number of polypoidal lesions on ICGA included: >5 (90%) and 2-4 (10%). Median duration of complete regression was 3 months (interquartile range: 2 to 6). Timing of complete regression at 2, 4, 6, 12 months was 50%, 9%, 18%, and 9%. At 1 year, 55% had complete regression, 40% had partial regression and 5% had no regression.
Conclusion : Following aflibercept treatment without PDT, most eyes with PCV had complete regression of polypoidal lesions on ICGA before 6 months, few had no regression at 1 year. These findings support consideration of aflibercept for PCV initially without PDT.
|
| |